Reduced fibrin clot permeability on admission and elevated E-selectin at 3 months as novel risk factors of residual pulmonary vascular obstruction in patients with acute pulmonary embolism.
E-selectin
Fibrin clot
Pulmonary embolism
Residual pulmonary vascular obstruction
Thrombin generation
Journal
Journal of thrombosis and thrombolysis
ISSN: 1573-742X
Titre abrégé: J Thromb Thrombolysis
Pays: Netherlands
ID NLM: 9502018
Informations de publication
Date de publication:
06 Nov 2023
06 Nov 2023
Historique:
accepted:
24
09
2023
medline:
7
11
2023
pubmed:
7
11
2023
entrez:
6
11
2023
Statut:
aheadofprint
Résumé
Residual pulmonary vascular obstruction (RPVO) is common following pulmonary embolism (PE) but its association with fibrin clot properties is poorly understood. We investigated whether prothrombotic state and hypofibrinolysis markers can identify patients with RPVO. In 79 normotensive noncancer patients (aged 56 ± 13.3 years) with acute PE, we determined fibrin clot permeability (K Patients with RPVO (n = 23, 29.1%) had at baseline higher simplified Pulmonary Embolism Severity Index (sPESI) (P = 0.004), higher N-terminal brain natriuretic propeptide (P = 0.006) and higher D-dimer (P = 0.044). Patients with versus without RPVO had lower K RPVO patients despite anticoagulation characterize with the formation of denser fibrin clots on admission and higher E-selectin at 3 months. Those parameters could be the potential novel RPVO risk factors that warrant further evaluation in an independent cohort.
Sections du résumé
BACKGROUND
BACKGROUND
Residual pulmonary vascular obstruction (RPVO) is common following pulmonary embolism (PE) but its association with fibrin clot properties is poorly understood. We investigated whether prothrombotic state and hypofibrinolysis markers can identify patients with RPVO.
METHODS
METHODS
In 79 normotensive noncancer patients (aged 56 ± 13.3 years) with acute PE, we determined fibrin clot permeability (K
RESULTS
RESULTS
Patients with RPVO (n = 23, 29.1%) had at baseline higher simplified Pulmonary Embolism Severity Index (sPESI) (P = 0.004), higher N-terminal brain natriuretic propeptide (P = 0.006) and higher D-dimer (P = 0.044). Patients with versus without RPVO had lower K
CONCLUSIONS
CONCLUSIONS
RPVO patients despite anticoagulation characterize with the formation of denser fibrin clots on admission and higher E-selectin at 3 months. Those parameters could be the potential novel RPVO risk factors that warrant further evaluation in an independent cohort.
Identifiants
pubmed: 37932588
doi: 10.1007/s11239-023-02901-y
pii: 10.1007/s11239-023-02901-y
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Wydział Lekarski, Uniwersytet Jagielloński Collegium Medicum
ID : N41/DBS/000682
Informations de copyright
© 2023. The Author(s).
Références
Lami D, Cellai AP, Antonucci E et al (2014) Residual perfusion defects in patients with pulmonary embolism are related to impaired fibrinolytic capacity. Thromb Res 134:737–741. https://doi.org/10.1016/j.thromres.2014.07.013
doi: 10.1016/j.thromres.2014.07.013
pubmed: 25074740
Planquette B, Ferré A, Peron J et al (2016) Residual pulmonary vascular obstruction and recurrence after acute pulmonary embolism. A single center cohort study. Thromb Res 148:70–75. https://doi.org/10.1016/j.thromres.2016.10.030
doi: 10.1016/j.thromres.2016.10.030
pubmed: 27815969
Sista AK, Klok FA (2018) Late outcomes of pulmonary embolism: the post-PE syndrome. Thromb Res 164:157–162. https://doi.org/10.1016/j.thromres.2017.06.017
doi: 10.1016/j.thromres.2017.06.017
pubmed: 28641836
Picart G, Robin P, Tromeur C et al (2020) Predictors of residual pulmonary vascular obstruction after pulmonary embolism: results from a prospective cohort study. Thromb Res 194:1–7. https://doi.org/10.1016/j.thromres.2020.06.004
doi: 10.1016/j.thromres.2020.06.004
pubmed: 32554255
Undas A (2017) Prothrombotic Fibrin Clot Phenotype in Patients with Deep Vein Thrombosis and Pulmonary Embolism: A New Risk Factor for Recurrence. Biomed Res Int. ; 2017: 8196256. https://doi.org/10.1155/2017/8196256
Undas A, Zawilska K, Ciesla-Dul M et al (2009) Altered fibrin clot structure/function in patients with idiopathic venous thromboembolism and in their relatives. Blood 114:4272–4278. https://doi.org/10.1182/blood-2009-05-222380
doi: 10.1182/blood-2009-05-222380
pubmed: 19690336
Zabczyk M, Plens K, Wojtowicz W et al (2017) Prothrombotic fibrin clot phenotype is Associated with Recurrent Pulmonary Embolism after discontinuation of anticoagulant therapy. Arterioscler Thromb Vasc Biol 37:365–373. https://doi.org/10.1161/ATVBAHA.116.308253
doi: 10.1161/ATVBAHA.116.308253
pubmed: 28062504
Undas A, Cieśla-Dul M, Drążkiewicz T et al (2012) Altered fibrin clot properties are associated with residual vein obstruction: effects of lipoprotein(a) and apolipoprotein(a) isoform. Thromb Res 130:e184–187. https://doi.org/10.1016/j.thromres.2012.06.005
doi: 10.1016/j.thromres.2012.06.005
pubmed: 22762941
Ząbczyk M, Natorska J, Janion-Sadowska A et al (2022) Isoprostane-8 and GDF-15 as novel markers of post-PE syndrome: relation with prothrombotic factors. Eur J Clin Invest 52:e13660. https://doi.org/10.1111/eci.13660
doi: 10.1111/eci.13660
pubmed: 34312860
Planquette B, Sanchez O, Marsh JJ et al (2018) Fibrinogen and the prediction of residual obstruction manifested after pulmonary embolism treatment. Eur Respir J 52:1801467. https://doi.org/10.1183/13993003.01467-2018
doi: 10.1183/13993003.01467-2018
pubmed: 30337447
pmcid: 9129142
Purdy M, Obi A, Myers D et al (2022) P- and E- selectin in venous thrombosis and non-venous pathologies. J Thromb Haemost 20:1056–1066. https://doi.org/10.1111/jth.15689
doi: 10.1111/jth.15689
pubmed: 35243742
pmcid: 9314977
Sullivan VV, Hawley AE, Farris DM et al (2003) Decrease in fibrin content of venous thrombi in selectin-deficient mice. J Surg Res 109:1–7. https://doi.org/10.1016/s0022-4804(02)00041-0
doi: 10.1016/s0022-4804(02)00041-0
pubmed: 12591228
Myers D Jr, Farris D, Hawley A et al (2002) Selectins influence thrombosis in a mouse model of experimental deep venous thrombosis. J Surg Res 108:212–221. https://doi.org/10.1006/jsre.2002.6552
doi: 10.1006/jsre.2002.6552
pubmed: 12505044
Xie Y, Duan Q, Wang L et al (2012) Genomic characteristics of adhesion molecules in patients with symptomatic pulmonary embolism. Mol Med Rep 6:585–590. https://doi.org/10.3892/mmr.2012.940
doi: 10.3892/mmr.2012.940
pubmed: 22684872
Darwish I, Fareed J, Brailovsky Y et al (2022) Dysregulation of biomarkers of hemostatic activation and inflammatory processes are Associated with adverse outcomes in Pulmonary Embolism. Clin Appl Thromb Hemost 28:10760296211064898. https://doi.org/10.1177/10760296211064898
doi: 10.1177/10760296211064898
pubmed: 35043658
pmcid: 8796112
Kansas GS (1996) Selectins and their ligands: current concepts and controversies. Blood 88:3259–3287
doi: 10.1182/blood.V88.9.3259.bloodjournal8893259
pubmed: 8896391
Bittar LF, Silva LQD, Orsi FLA et al (2020) Increased inflammation and endothelial markers in patients with late severe post-thrombotic syndrome. PLoS ONE 15:e0227150. https://doi.org/10.1371/journal.pone.0227150
doi: 10.1371/journal.pone.0227150
pubmed: 31945777
pmcid: 6964981
Ząbczyk M, Natorska J, Janion-Sadowska A et al (2020) Prothrombotic fibrin clot properties associated with NETs formation characterize acute pulmonary embolism patients with higher mortality risk. Sci Rep 10:11433. https://doi.org/10.1038/s41598-020-68375-7
doi: 10.1038/s41598-020-68375-7
pubmed: 32651425
pmcid: 7351737
Pruszczyk P, Skowrońska M, Ciurzyński M et al (2021) Assessment of pulmonary embolism severity and the risk of early death. Pol Arch Intern Med 131:16134. https://doi.org/10.20452/pamw.16134
doi: 10.20452/pamw.16134
pubmed: 34775739
Ciurzyński M, Kurzyna M, Kopeć G et al (2022) An expert opinion of the polish Cardiac Society Working Group on Pulmonary circulation on screening for chronic thromboembolic pulmonary hypertension patients after acute pulmonary embolism: update. Kardiol Pol 80:723–732. https://doi.org/10.33963/KP.a2022.0141
doi: 10.33963/KP.a2022.0141
pubmed: 35665906
Stepien K, Nowak K, Szlosarczyk B et al (2022) Clinical characteristics and long-term outcomes of MINOCA accompanied by active Cancer: a retrospective insight into a Cardio-Oncology Center Registry. Front Cardiovasc Med 9:785246. https://doi.org/10.3389/fcvm.2022.785246
doi: 10.3389/fcvm.2022.785246
pubmed: 35669480
pmcid: 9163819
Stepien K, Nowak K, Zalewski J et al (2019) Extended treatment with non-vitamin K antagonist oral anticoagulants versus low-molecular-weight heparins in cancer patients following venous thromboembolism. A pilot study. Vascul Pharmacol 120:106567. https://doi.org/10.1016/j.vph.2019.106567
doi: 10.1016/j.vph.2019.106567
pubmed: 31158568
Stępień K, Siudut J, Konieczyńska M et al (2023) Effect of high-dose statin therapy on coagulation factors: lowering of factor XI as a modifier of fibrin clot properties in coronary artery disease. Vascul Pharmacol 149:107153. https://doi.org/10.1016/j.vph.2023.107153
doi: 10.1016/j.vph.2023.107153
pubmed: 36774992
Pieters M, Philippou H, Undas A et al (2018) An international study on the feasibility of a standardized combined plasma clot turbidity and lysis assay: communication from the SSC of the ISTH. J Thromb Haemost 16:1007–1012. https://doi.org/10.1111/jth.14002
doi: 10.1111/jth.14002
pubmed: 29658191
Zalewski J, Stepien K, Nowak K et al (2020) Delayed Thrombin Generation is Associated with minor bleedings in venous thromboembolism patients on Rivaroxaban: usefulness of calibrated Automated Thrombography. J Clin Med 9:2018. https://doi.org/10.3390/jcm9072018
doi: 10.3390/jcm9072018
pubmed: 32605001
pmcid: 7409038
Bonnefoy PB, Margelidon-Cozzolino V, Catella-Chatron J et al (2019) What’s next after the clot? Residual pulmonary vascular obstruction after pulmonary embolism: from imaging finding to clinical consequences. Thromb Res 184:67–76. https://doi.org/10.1016/j.thromres.2019.09.038
doi: 10.1016/j.thromres.2019.09.038
pubmed: 31710860
Chang Y, Moon JY, Park JH et al (2021) Predictors of residual pulmonary vascular obstruction after anticoagulation monotherapy in patients with intermediate-risk pulmonary embolism. J Thorac Dis 13:4217–4227. https://doi.org/10.21037/jtd-21-403
doi: 10.21037/jtd-21-403
pubmed: 34422350
pmcid: 8339779
Pietrasik A, Gąsecka A, Smyk JM et al (2022) Acute-on-chronic pulmonary embolism and concomitant paradoxical embolism: two diseases, one intervention. Pol Arch Intern Med 132:16155. https://doi.org/10.20452/pamw.16155
doi: 10.20452/pamw.16155
pubmed: 34851065
Chopard R, Genet B, Ecarnot F et al (2017) Detection of residual pulmonary vascular obstruction by ventilation-perfusion lung scan late after a First Pulmonary Embolism. Am J Cardiol 119:1883–1889. https://doi.org/10.1016/j.amjcard.2017.03.002
doi: 10.1016/j.amjcard.2017.03.002
pubmed: 28400030
Meneveau N, Ider O, Seronde MF et al (2013) Long-term prognostic value of residual pulmonary vascular obstruction at discharge in patients with intermediate- to high-risk pulmonary embolism. Eur Heart J 34:693–701. https://doi.org/10.1093/eurheartj/ehs365
doi: 10.1093/eurheartj/ehs365
pubmed: 23103660
Undas KW, Siudut J, Ząbczyk M (2022) Unfavorably altered fibrin clot properties are associated with recurrent venous thromboembolism in patients following postdischarge events. Pol Arch Intern Med 132:16326. https://doi.org/10.20452/pamw.16326
doi: 10.20452/pamw.16326
pubmed: 36006621
Scott EM, Ariëns RA, Grant PJ (2004) Genetic and environmental determinants of fibrin structure and function: relevance to clinical disease. Arterioscler Thromb Vasc Biol 24:1558–1566. https://doi.org/10.1161/01.ATV.0000136649.83297.bf
doi: 10.1161/01.ATV.0000136649.83297.bf
pubmed: 15217804
de Vries JJ, Snoek CJM, Rijken DC et al (2020) Effects of post-translational modifications of fibrinogen on clot formation, clot structure, and Fibrinolysis: a systematic review. Arterioscler Thromb Vasc Biol 40:554–569. https://doi.org/10.1161/ATVBAHA.119.313626
doi: 10.1161/ATVBAHA.119.313626
pubmed: 31914791
pmcid: 7043730
Ząbczyk M, Stachowicz A, Natorska J et al (2019) Plasma fibrin clot proteomics in healthy subjects: relation to clot permeability and lysis time. J Proteom 208:103487. https://doi.org/10.1016/j.jprot.2019.103487
doi: 10.1016/j.jprot.2019.103487
Stachowicz A, Siudut J, Suski M et al (2017) Optimization of quantitative proteomic analysis of clots generated from plasma of patients with venous thromboembolism. Clin Proteom 14:38. https://doi.org/10.1186/s12014-017-9173-x
doi: 10.1186/s12014-017-9173-x
Watany MM, Abdou S, Elkolaly R et al (2022) Evaluation of admission levels of P, E and L selectins as predictors for thrombosis in hospitalized COVID-19 patients. Clin Exp Med 22:567–575. https://doi.org/10.1007/s10238-021-00787-9
doi: 10.1007/s10238-021-00787-9
pubmed: 35061142
pmcid: 8778493
Culmer DL, Dunbar ML, Hawley AE et al (2017) E-selectin inhibition with GMI-1271 decreases venous thrombosis without profoundly affecting tail vein bleeding in a mouse model. Thromb Haemost 117:1171–1181. https://doi.org/10.1160/TH16-04-0323
doi: 10.1160/TH16-04-0323
pubmed: 28300869
Myers DD Jr, Ning J, Lester P et al (2022) E-selectin inhibitor is superior to low-molecular-weight heparin for the treatment of experimental venous thrombosis. J Vasc Surg Venous Lymphat Disord 10:211–220. https://doi.org/10.1016/j.jvsv.2020.12.086
doi: 10.1016/j.jvsv.2020.12.086
pubmed: 33872819
Ortel TL, Neumann I, Ageno W et al (2020) American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv 4:4693–4738. https://doi.org/10.1182/bloodadvances.2020001830
doi: 10.1182/bloodadvances.2020001830
pubmed: 33007077
pmcid: 7556153
Bruinstroop E, Klok FA, Van De Ree MA et al (2009) Elevated D-dimer levels predict recurrence in patients with idiopathic venous thromboembolism: a meta-analysis. J Thromb Haemost 7:611–618. https://doi.org/10.1111/j.1538-7836.2009.03293.x
doi: 10.1111/j.1538-7836.2009.03293.x
pubmed: 19175498
Kaczyńska A, Kostrubiec M, Pacho R et al (2008) Elevated D-dimer concentration identifies patients with incomplete recanalization of pulmonary artery thromboemboli despite 6 months anticoagulation after the first episode of acute pulmonary embolism. Thromb Res 122:21–25. https://doi.org/10.1016/j.thromres.2007.08.020
doi: 10.1016/j.thromres.2007.08.020
pubmed: 17931694
Aranda C, Peralta L, Gagliardi L et al (2021) A significant decrease in D-dimer concentration within one month of anticoagulation therapy as a predictor of both complete recanalization and risk of recurrence after initial pulmonary embolism. Thromb Res 202:31–35. https://doi.org/10.1016/j.thromres.2021.02.033
doi: 10.1016/j.thromres.2021.02.033
pubmed: 33711756
Wiliński J, Skwarek A, Borek R et al (2022) Right ventricular wall thickness indexed to body surface area as an echocardiographic predictor of acute pulmonary embolism in high-risk patients. Kardiol Pol 80:205–207. https://doi.org/10.33963/KP.a2021.0180
doi: 10.33963/KP.a2021.0180
pubmed: 34904219
Delluc A, Wang TF (2021) How to treat incidental pulmonary embolism in cancer patients? Recent advances. Kardiol Pol 79:1305–1310. https://doi.org/10.33963/KP.a2021.0164
doi: 10.33963/KP.a2021.0164
pubmed: 34845714